Key Takeaways SEM formed a JV with Vibra Healthcare to operate Southern Kentucky Rehabilitation Hospital in Bowling Green.The 76-bed facility provides acute inpatient rehab for stroke, brain injury and spinal injury patients.The deal supports SEM's rehab growth strategy as revenues rose 4.7% in the first nine months of 2025.Select Medical Holdings Corporation (SEM) has entered into a joint venture (JV) with Vibra Healthcare to enhance access to inpatient rehabilitation services in Southern Kentucky, marking ...

A strong stock as of late has been Charles River Laboratories (CRL) . Shares have been marching higher, with the stock up 11.3% over the past month. The stock hit a new 52-week high of $208.69 in the previous session. Charles River has gained 4.4% since the start of the year compared to the 5.4% gain for the Zacks Medical sector and the 10% return for the Zacks Medical Services industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, having beaten the Zacks Con ...

滨州日报/滨州网讯 "真没想到，前几天在我们乡镇卫生院做的肝功能和肾功能检查，到市医院还能用， 省了100多块钱，真是太好了！"在邹平市人民医院肾内科诊室，前来就诊的王先生对检查检验结果互认 工作赞不绝口。 近年来，为进一步提升群众看病就医体验，市卫生健康委聚力推进检查检验结果互认共享平台建设和应 用，降低患者就医费用，真正把群众关心事办成民生暖心事。截至目前，全市已有43家医疗机构实现 429项检查检验数据互通，累计为患者节省就医费用超5000万元。在近日召开的国家卫健委"介绍为民服 务八件实事有关情况"新闻发布会上，滨州这一做法被点名表扬。 彰显互认成效，降低就医负担"惠民生" 检查检验结果互认共享平台的建成和应用，真正实现了"让信息跑路"，患者跨机构就医时无需再携带纸 质检查报告、影像资料等，接诊医师在医生端可直接调阅，并根据诊疗需要实施互认。不仅大幅缩短了 患者检验检查排队等待时间，提高了医疗服务效率，又有效减少了重复检查检验，降低了患者就医费用 和负担，真正达到省时、省力、省钱，切实提高群众就医获得感和满意度。 聚焦提质扩面，开启平台应用"新航道" 2025年，滨州市委将"深化拓展互认共享工作成效" ...

经验交流环节，集团各成员单位代表立足实践分享真知，多维度展现协同共建成果。乳山市中医院党委 书记宋君成分享跨区域精准帮扶成效，推动三甲资源扎根乳山、辐射威海；龙口市中医医院副院长周云 龙围绕县域医疗服务圈，解读"接得住、转得顺、治得好"核心要义，提供县域协同范本；高新区医院院 长宋波详解人财物统一管理机制，诠释资源无壁垒、服务零距离的紧密型优势；莱山街道社区卫生服务 中心副院长王玲立足基层，分享筑牢健康服务最后一公里的举措，彰显健康守门人担当；烟台山医院党 委办公室主任兼人事科科长孙晖深度解读《党建"四联"引领 品管圈精准突破》，从党建"四联"打破壁 垒、凝聚同心，到品管圈聚焦细节、精准发力，展示了集团在破解发展难题、提升服务品质上的务实举 措。 此次会议既是三年试点总结会，更是高质量发展新起点。未来，集团将锚定"健康中国2030"战略航向， 秉持"一家人、一条心、一股劲"信念与"管理协同、服务同质、资源共享"理念，以更紧密的协作、更务 实的举措推动三甲优质资源精准下沉、夯实基层服务能力，让优质医疗直达民心。收官2025、启航 2026，烟台山紧密型城市医疗集团将深耕基层、延伸服务触角，在区域医疗协同发展道路 ...

第21批援圭亚那中国医疗队中医科近日参与乔治敦公立医院疼痛联合门诊，探索中医药与现代医学协同诊疗新模式，围绕疼痛管理、功能恢复及合理用药 开展实践，为当地患者提供更多安全、有效的治疗选择。 扬子晚报/紫牛新闻记者吕彦霖 在近期一次联合门诊中，中医科医生魏浩洋接诊一名足底筋膜炎患者，该患者行走跛行，就诊时疼痛评分达9分。按原有流程，患者开具镇痛药物后需再 次预约后续物理治疗。魏浩洋在与团队沟通后，现场采用"筋针"疗法进行治疗。进针后患者疼痛明显缓解，评分降至4分，行走能力显著改善。使患者在 本次就诊中就能看到立竿见影的效果。 "筋针"是一种融合传统针灸与现代软组织损伤学说的针刺疗法，主要用于肌筋膜疼痛等"筋病"，具有浅刺、起效快、刺激轻等特点，有助于减少患者在等 待期间对镇痛药物的依赖。接受本次治疗的患者表示，首次接触针灸即感过程舒适、效果明显，第一次体验到中医的神奇，并主动预约后续治疗。 通讯员李妍雨 医疗队队长李欢送表示，中医中药治疗在疼痛管理与功能恢复方面具有独特优势。参与联合门诊不仅为患者提供了多元化、非药物的治疗选择，也为当地 医务人员了解中医提供了实践平台。下一步，医疗队将持续参与临床诊疗，并通过技 ...

近日，省医保局、省卫生健康委联合印发《关于整合规范综合诊查类等相关医疗服务项目价格的通 知》，2025年12月25日起对全省综合诊查类、精神治疗类和康复类医疗服务项目价格进行整合规范。 对于此次整合规范中由原政府指导价管理调整为市场调节价管理的项目，通知设置了过渡期：自政策执 行之日起半年内，医疗机构自主确定的价格不得高于原政府指导价。相关管理需严格遵循《山西省医疗 保障局山西省卫生健康委员会关于进一步做好实行市场调节价的医疗服务项目价格管理工作的通知》 （晋医保发〔2019〕26号）相关要求进行管理。 通知要求，各医疗机构必须严格执行医疗服务项目价格，认真落实价格公示和"一日清单"制度，严禁擅 自提高收费标准或分解项目收费。（记者韩林芳） 根据通知，我省将综合诊查类、精神治疗类和康复类医疗服务项目价格分别整合规范为36项、10项、17 项，各医疗机构可在核定价格基础上实行向下浮动。同时，取消原综合诊查类项目59项、原精神治疗类 项目25项、原康复类项目44项。 通知明确，我省原"省优秀专家、享受国特贴专家、全国名中医门诊辨证论治、国医大师门诊中医辨证 论治"门诊诊察项目将按照"知名专家"项目执行，实行市场调 ...

Key Takeaways MD shares rose 55.2% in six months, outperforming the industry's 6.7% gain on improving fundamentals.Pediatrix Medical is seeing higher same-unit revenue from better payer mix, collections and patient acuity.MD generated $138.1M in Q3 operating cash flow, up sharply from $95.7M a year earlier.Pediatrix Medical Group, Inc. (MD) is well-poised for growth, driven by higher collection activity, improved patient acuity, an increase in contract administrative fees, a favorable payor mix and strategi ...

转自：新华财经 前言：2025年1月，国家卫生健康委发布全系统为民服务八件实事，这是卫生健康系统第一次向社会公 开承诺开展服务的内容。2025年度，聚焦群众"心上事"，江苏卫生健康系统集中力量和资源，推动实事 落地落实。 血液透析是终末期肾病患者维系生命的重要手段，治疗须长期坚持、规律进行。然而，部分县域血透服 务资源不足，患者往往需要辗转奔波于大医院，加重了治疗负担与经济压力。为推动县域血液透析服务 可及性，江苏省卫生健康委全面开展摸排评估、分类推进建设、加强质量监管，有力推动县域血透服务 提速扩面。截至2025年底，全省人口超过10万的县域已全部具备血透服务能力，切实筑牢基层患者 的"生命线"。 健全制度体系，加强血透服务供给 在工作推进中，江苏坚持"一县一策"，通过集中攻关与分类指导，系统破解服务瓶颈，稳步扩大有效供 给。在布局上，聚焦人口超过10万的县，全力消除服务空白点，并以此辐射带动周边地区。针对人员能 力不足的问题，组织开展专项培训，加快培养具备独立执业能力的血透专业技术人员。针对设备短板， 采取"填平补齐"与"更新换代"相结合的方式，精准提升县域血透机构的设施装备水平。 部分终末期肾病患者每周 ...

Company Performance - Medpace (MEDP) closed at $561.65, reflecting a -1.27% change from the previous day, underperforming the S&P 500's loss of 0.74% [1] - Prior to the latest trading session, Medpace shares had declined by 2.54%, contrasting with the Medical sector's loss of 0.8% and the S&P 500's gain of 0.79% [1] Earnings Forecast - Medpace is expected to report an EPS of $4.18, representing a 13.9% increase from the same quarter last year [2] - Revenue is forecasted to be $681.17 million, indicating a growth of 26.94% compared to the corresponding quarter of the prior year [2] Full Year Estimates - For the full year, analysts project earnings of $14.8 per share and revenue of $2.5 billion, reflecting increases of +17.18% and +18.68% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Medpace are important as they indicate shifts in near-term business trends, with positive revisions suggesting optimism about the business outlook [4] - The Zacks Rank system, which incorporates these estimate changes, currently assigns Medpace a rank of 2 (Buy) [6] Valuation Metrics - Medpace has a Forward P/E ratio of 38.45, which is a premium compared to the industry average Forward P/E of 15.5 [7] - The company also has a PEG ratio of 2.15, compared to the Medical Services industry's average PEG ratio of 1.72 [7] Industry Context - The Medical Services industry, which includes Medpace, has a Zacks Industry Rank of 165, placing it in the bottom 34% of over 250 industries [8] - Historically, the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Viewpoint - Algernon Health Inc. has successfully closed a non-brokered private placement financing, raising a total of CAD $858,000 to support its Alzheimer's Disease program and other operational expenses [2][4]. Financing Details - The total gross proceeds from the fourth tranche amounted to CAD $117,501 from the sale of 1,678,586 units at an issue price of CAD $0.07 per unit [2]. - The overall financing raised CAD $857,001 from the sale of 12,242,872 units across all tranches [2]. Insider Participation - Certain insiders participated in the fourth tranche, contributing CAD $32,501, which is classified as a "related party transaction" under MI 61-101 [3]. - The company is relying on exemptions from valuation and minority shareholder approval requirements as the insider purchases did not exceed 25% of the company's market capitalization [3]. Use of Proceeds - Proceeds from the offering will be allocated towards advancing the company's Alzheimer's Disease program, including the opening of its first U.S. clinic, as well as for general administrative expenses and working capital [4]. Company Overview - Algernon Health is focused on providing brain-optimized PET scanning services for early-stage detection of Alzheimer's Disease and other neurological conditions through a planned network of clinics in North America [7].